Retatrutide / Cagrilintide Blend

Status

No approved product. Drugs@FDA lists no FDA-approved product for this blend or for either component (checked 25 October 2026); other countries were not verified. Both are investigational compounds; Eli Lilly states that retatrutide is investigational and not FDA approved. No study of the blend as a combination was identified in the sources reviewed for this entry.

What it is

A community blend combining an incretin agonist with an amylin analogue.

What published research measured

Combines two investigational agents, neither of which is FDA-approved, and no approval elsewhere is listed in this entry's sources: a triple GLP-1, GIP and glucagon receptor agonist and a long-acting amylin analogue. Both have individual phase 2 data — retatrutide has reported large mean weight reductions in its trials, and cagrilintide has been studied both alone and in a separate fixed combination with semaglutide that is itself still in development. The critical point is that combining two unapproved compounds means this entry's sources identify no study of the pair's safety or interaction, and neither component has completed the phase 3 programme that determines what its own risks are. No blend in this category has been studied as a blend. Trial evidence, where it exists, was generated on single agents given alone; no published study of the combination for interaction, additive adverse effects or altered pharmacokinetics was identified in the sources reviewed for this entry. Two practical consequences follow. A multi-compound vial is a compounded preparation, so the stability of each component in the presence of the others, and over the life of the vial, is generally unstudied. If a reaction occurs, multiple components make it difficult to attribute it to one of them, which is one reason clinical pharmacology usually introduces agents one at a time.

Source

Eli Lilly, “What to know about retatrutide” — retatrutide is investigational and not FDA approved Primary source

Sources

• Eli Lilly, “What to know about retatrutide” — retatrutide is investigational and not FDA approved